The firm’s Warren Burns helped secure a significant court ruling that pushes forward consumers’ antitrust claims against EpiPen manufacturers and distributors. Those companies, Pfizer and Mylan, have been under scrutiny since hiking the price of the epinephrine auto-injector in 2016, resulting in price increases of more than 600 percent since 2007. A federal district court judge in Kansas has upheld the majority of the plaintiffs’ claims, saying that the class has sufficiently alleged a conspiracy. “This is an important case for all Americans,” says Mr. Burns, co-lead counsel for the plaintiffs.  “The judge’s order means that we are one step closer to making the defendants pay for the exorbitant prices they foisted on our clients. And it sets an important precedent that should make other drug companies think twice before they engage in such practices.”

For more go to the Law360 article here.